Trial reportScientific reports2016
Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.
Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Comparative Digital Estrogen Receptor Alpha (ERα) Expression Analysis in Benign and Malignant Prostate Tissue of Men and Dogs.The Prostate · 2026Article
- Tracing the Evolution of Sex Hormones and Receptor-Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Genes Co-Expressed withInternational journal of molecular sciences · 2024Article
- Lifelong exercise training promotes the remodelling of the immune system and prostate signalome in a rat model of prostate carcinogenesis.GeroScience · 2024Article
- Histopathological analysis potential for unveiling hormone signaling in endocrine-related tumors.Endocrine oncology (Bristol, England) · 2024Review
- Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features.Frontiers in oncology · 2024Article
- Review
- Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.Biomedicines · 2023Review
- The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches.Biomedicines · 2023Review
- Prognostic value of estrogen receptors in patients who underwent prostatectomy for non‑metastatic prostate cancer.Oncology letters · 2023Article
- Targeting the formation of estrogens for treatment of hormone dependent diseases-current status.Frontiers in pharmacology · 2023Review
- miR-18a-5p Is Involved in the Developmental Origin of Prostate Cancer in Maternally Malnourished Offspring Rats: A DOHaD Approach.International journal of molecular sciences · 2022Article
- Signal Crosstalk and the Role of Estrogen Receptor beta (ERβ) in Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022Review
- Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.Journal for immunotherapy of cancer · 2022Review
- Association between estrogen receptor β polymorphisms and prostate cancer in a Slovak population.Oncology letters · 2021Article
- Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.International journal of molecular sciences · 2021Review
- Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer.Cancers · 2021Review
- Article
- A Systematic Study of the Impact of Estrogens and Selective Estrogen Receptor Modulators on Prostate Cancer Cell Proliferation.Scientific reports · 2020Article
- Plasma aromatase as a sensitive and selective potential biomarker of bladder cancer and its role in tumorigenesis.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgens are considered important in normal prostate physiology and prostate cancer (PCa) pathogenesis. However, androgen-targeted treatment preventing PCa recurrence is still lacking. This indicates additional mediators contributing to cancer development. We sought to determine the prognostic significance of estrogen receptors, ERα and -β, and the aromatase enzyme in PCa. Tissue microarrays were created from 535 PCa patients treated with radical prostatectomy. Expression of ERα, ERβ and aromatase were evaluated using immunohistochemistry. Representative tumor epithelial (TE) and tumor stromal (TS) areas were investigated separately. Survival analyses were used to evaluate the markers correlation to PCa outcome. In univariate analyses, ERα in TS was associated with delayed time to clinical failure (CF) (p = 0.042) and PCa death (p = 0.019), while ERβ was associated with reduced time to biochemical failure (BF) (p = 0.002). Aromatase in TS and TE was associated with increased time to BF and CF respectively (p = 0.016, p = 0.046). Multivariate analyses supported these observations, indicating an independent prognostic impact of all markers. When stratifying the analysis according to different surgical centers the results were unchanged. In conclusion, significant prognostic roles of ERα, ERβ and aromatase were discovered in the in PCa specimens of our large multicenter cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.